Parkinson’sDiseaseWRAP:

Landmark Advances in Parkinson’s Disease

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

September 15, 2009

Expiration Date:

September 15, 2011

Intended Audience:

The educational activity is designed for all physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors from the fields of neurology, movement disorders, geriatrics, geropsychiatry, internal medicine, primary care, and related disciplines who care for patients with Parkinson’s Disease.

Registration:

Enrollment for this MedicineWRAP is complimentary, and clinicians are invited to participate in this CME-certified MedicineWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent
educational grant from
Teva Neuroscience, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

C. Warren Olanow, MD, FRCPC
Henry P. and Georgette Goldschmidt Professor
Chairman Emeritus, Department of Neurology
Professor, Department of Neuroscience
Director, Robert and John M. Bendheim Parkinson's Disease Center
Mount Sinai School of Medicine
New York, New York

Faculty Disclosures:

Dr. Olanow reports that he has received consultant fees from: Boehringer Ingelheim; Ceregene, Inc., Merck Serono International, SA; Novartis; Solvay Pharmaceuticals, Inc.; and Teva Neuroscience

Program Managers and Disclosures

Gideon Bosker, MD
Nothing to Disclose

Milo Falcon
Nothing to Disclose

Denise Leary
Nothing to Disclose

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

• Learn to risk stratify, screen for, and evaluate patients with suspected or possible risk for Parkinson’s Disease (PD), and identify optimal therapeutic approaches.

• Learn to undertake a systematic evaluation of patients at risk for PD, including neurological exam, radiological examination, and appropriate laboratory markers.

• Learn evidence-based approaches to reducing pro gression of PD, and sequencing pharmacological ap proaches in patients requiring monotherapy combination therapy for PD.

• Learn how to select safe and effective pharmacotherapy for treatment of PD.

• Learn how issues related to dosing, dosing schedules, compliance, persistence, and adherence may impact patient preferences and outcomes in patients with PD.

• Learn how issues related to drug interactions, side ef fects, and combination therapy may impact drug selec tion strategies and outcomes in patients with PD.

• Learn how landmark trials and analyses focusing on disease modification
  

Disclaimer:

Copyright © 2009 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this MedicineWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this MedicineWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this MedicineWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This MedicineWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This MedicineWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved